Test Code LAB977 Dihydrotestosterone, Serum
Additional Codes
DIHYDROTES
Reporting Name
Dihydrotestosterone, SSCH Clinical System Name: Dihydrotestosterone
Useful For
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy
Evaluating patients with possible 5-alpha reductase deficiency
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Collect 2.0 mL whole blood in a Red top.
Specimen Type
SerumSpecimen Minimum Volume
0.6 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 90 days | ||
Ambient | 28 days |
Day(s) Performed
Monday, Wednesday, Friday
TAT: 4 - 10 days
Performing Laboratory
Mayo Clinic Laboratories in RochesterMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Portions of this test are covered by patents held by Quest Diagnostics
Method Description
High Performance Liquid Chromatography with Triple Quad Tandem Mass Spectrometer Deuterated stable isotope of dihydrotestosterone (13C3-DHT) is added to a 0.5 mL serum sample as internal standard. The DHT and internal standard are extracted from the sample by liquid/liquid extraction. This is followed by high performance liquid chromatography on a Cohesive LX4 System and analysis on a tandem mass spectrometer equipped with an electrospray ion source.(Unpublished Mayo Method)
Reference Values
Males
Cord blood: ≤100 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
12.1 years |
≤200 |
Stage III |
13.6 years |
80-330 |
Stage IV |
15.1 years |
220-520 |
Stage V |
18 years |
240-650 |
>19 years: 112-955 pg/mL
Females
Cord blood: ≤50 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
10.5 years |
≤300 |
Stage III |
11.6 years |
≤300 |
Stage IV |
12.3 years |
≤300 |
Stage V |
14.5 years |
≤300 |
20-55 years: ≤300 pg/mL
>55 years: ≤128 pg/mL
1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826
2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82642
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DHTS | Dihydrotestosterone, S | 1848-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
81479 | Dihydrotestosterone, S | 1848-1 |
Testing Algorithm
For more information see Steroid Pathways.
Special Instructions
Report Available
2 to 8 daysReject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Aliases: 5-a-dihydrotestosterone; 5-Alpha-Dihydrotestosterone; Allodihydrotestosterone; Androstanolone; DHT; Serum Dihydrotestosterone; Stanolone